GlaxoSmithKline has high hopes for its standalone consumer health business, Haleon, when it launches in July. Haleon is targeting organic annual sales growth of 4-6% over the medium term, which CEO-designate Brian McNamara said will be achieved, in part, by reaching new consumers with its products.
GSK Consumer Healthcare’s Tess Player told HBW Insight that Haleon will pioneer new ways to bring self-care to under-served sections...





